Cameron Padilla,Constantine A Stratakis,Christina Tatsi
{"title":"The phenotype of the pediatric patient with Cushing syndrome but without obesity.","authors":"Cameron Padilla,Constantine A Stratakis,Christina Tatsi","doi":"10.1093/ejendo/lvae114","DOIUrl":null,"url":null,"abstract":"OBJECTIVE\r\nCushing syndrome (CS) often presents with obesity that is not as severe in children as it is in adults. The role of obesity in the severity of metabolic syndrome in children with CS has not been studied. This study evaluates whether pediatric patients with CS have obesity-specific differences in their demographic, biochemical and presenting findings.\r\n\r\nDESIGN\r\nCohort study.\r\n\r\nMETHODS\r\nWe analyzed 273 patients with young onset of CS at ≤ 18 years old and classified as patients with or without obesity based on their BMI z-scores.\r\n\r\nRESULTS\r\nPatients without obesity (n=84, 31%) were more frequently females with an older age of onset compared to patients with obesity (n=189, 69%). Consistent with their older age, patients without obesity were also more likely to have advanced Tanner stages. Patients with and without obesity had similar duration of disease, but patients with obesity showed higher markers of hypercortisolemia (urinary free cortisol). A higher prevalence of hypertension and insulin resistance was seen in patients with obesity than those without obesity, adjusting for urinary free cortisol (UFC) (p < .05 for all comparisons). While fatty liver disease was not statistically different among the entire cohort, elevated alanine transaminase (ALT) and metabolic dysfunction-associated steatotic liver disease (MASLD) scores were more common in ACTH-dependent CS patients with obesity (p < .05).\r\n\r\nCONCLUSIONS\r\nWeight gain appears to mediate some but not all the cortisol-associated complications in pediatric CS. Therefore, obesity may be a modifiable risk factor among these patients.","PeriodicalId":11884,"journal":{"name":"European Journal of Endocrinology","volume":"8 1","pages":""},"PeriodicalIF":5.3000,"publicationDate":"2024-09-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"European Journal of Endocrinology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1093/ejendo/lvae114","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"ENDOCRINOLOGY & METABOLISM","Score":null,"Total":0}
引用次数: 0
Abstract
OBJECTIVE
Cushing syndrome (CS) often presents with obesity that is not as severe in children as it is in adults. The role of obesity in the severity of metabolic syndrome in children with CS has not been studied. This study evaluates whether pediatric patients with CS have obesity-specific differences in their demographic, biochemical and presenting findings.
DESIGN
Cohort study.
METHODS
We analyzed 273 patients with young onset of CS at ≤ 18 years old and classified as patients with or without obesity based on their BMI z-scores.
RESULTS
Patients without obesity (n=84, 31%) were more frequently females with an older age of onset compared to patients with obesity (n=189, 69%). Consistent with their older age, patients without obesity were also more likely to have advanced Tanner stages. Patients with and without obesity had similar duration of disease, but patients with obesity showed higher markers of hypercortisolemia (urinary free cortisol). A higher prevalence of hypertension and insulin resistance was seen in patients with obesity than those without obesity, adjusting for urinary free cortisol (UFC) (p < .05 for all comparisons). While fatty liver disease was not statistically different among the entire cohort, elevated alanine transaminase (ALT) and metabolic dysfunction-associated steatotic liver disease (MASLD) scores were more common in ACTH-dependent CS patients with obesity (p < .05).
CONCLUSIONS
Weight gain appears to mediate some but not all the cortisol-associated complications in pediatric CS. Therefore, obesity may be a modifiable risk factor among these patients.
期刊介绍:
European Journal of Endocrinology is the official journal of the European Society of Endocrinology. Its predecessor journal is Acta Endocrinologica.
The journal publishes high-quality original clinical and translational research papers and reviews in paediatric and adult endocrinology, as well as clinical practice guidelines, position statements and debates. Case reports will only be considered if they represent exceptional insights or advances in clinical endocrinology.
Topics covered include, but are not limited to, Adrenal and Steroid, Bone and Mineral Metabolism, Hormones and Cancer, Pituitary and Hypothalamus, Thyroid and Reproduction. In the field of Diabetes, Obesity and Metabolism we welcome manuscripts addressing endocrine mechanisms of disease and its complications, management of obesity/diabetes in the context of other endocrine conditions, or aspects of complex disease management. Reports may encompass natural history studies, mechanistic studies, or clinical trials.
Equal consideration is given to all manuscripts in English from any country.